SFJ X (PhaseBio)

SFJ X supported a clinical co-development deal with PhaseBio to fund and manage clinical development of PB2452 which is an antidote to Brillinta, an oral anti-platelet medicine. Reversal of this anti-clotting activity is needed to reduce the risk of bleeding in high risk situations such as trauma or surgery. The phase 3 primary endpoint was positive and the company received Orphan Drug Designation. The drug has been partnered with SERB, a specialty pharmaceutical company, who is responsible for commercialization in the U.S. A BLA filing is expected in late 2026.